# A Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older Adults

> **NCT07628049** · PHASE1,PHASE2 · RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 1456 (estimated)

## Conditions studied

- Respiratory Syncytial Virus Infections+Metapneumovirus

## Interventions

- **BIOLOGICAL:** RSV/hMPV_V low dose vaccine
- **BIOLOGICAL:** RSV/hMPV_V medium dose vaccine
- **BIOLOGICAL:** RSV/hMPV_V high dose vaccine
- **BIOLOGICAL:** RSV/hMPV_W low dose vaccine
- **BIOLOGICAL:** RSV/hMPV_W medium dose vaccine
- **BIOLOGICAL:** RSV/hMPV_W high dose vaccine
- **BIOLOGICAL:** RSV/hMPV_X low dose vaccine
- **BIOLOGICAL:** RSV/hMPV_X medium dose vaccine
- **BIOLOGICAL:** RSV/hMPV_X high dose vaccine
- **BIOLOGICAL:** hMPV_Y low dose vaccine
- **BIOLOGICAL:** hMPV_Y medium dose vaccine
- **BIOLOGICAL:** hMPV_Y high dose vaccine
- **BIOLOGICAL:** hMPV_Z low dose vaccine
- **BIOLOGICAL:** hMPV_Z medium dose vaccine
- **BIOLOGICAL:** hMPV_Z high dose vaccine
- **BIOLOGICAL:** Control vaccine
- **COMBINATION_PRODUCT:** Placebo

## Key facts

- **NCT ID:** NCT07628049
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-05
- **Primary completion:** 2029-04-05
- **Final completion:** 2029-04-05
- **Target enrollment:** 1456 (ESTIMATED)
- **Last updated:** 2026-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07628049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07628049, "A Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older Adults". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07628049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*